Palpu Hazel, MD
Child & Adolescent Psychiatry · Scottsdale, AZNPI 1518901974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 582 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,173 and has fallen 71.8% since, to $894 in 2024. Among child & adolescent psychiatry clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 582 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Corium, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Tris Pharma Inc$804
- plus $5K from 20 others
What the payments were for
- Food & beverage$12,44399%
- Education$1881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,694 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,554 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,535 |
| Corium, LLC | 48 | $1,304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $1,037 |
| Tris Pharma Inc | 54 | $804 |
| Lundbeck LLC | 37 | $630 |
| Teva Pharmaceuticals USA, Inc. | 23 | $496 |
| Axsome Therapeutics, Inc. | 16 | $472 |
| Ironshore Pharmaceuticals Inc. | 23 | $446 |
| Johnson & Johnson | 18 | $434 |
| Sunovion Pharmaceuticals Inc. | 22 | $397 |
| Alkermes, Inc. | 13 | $380 |
| Supernus Pharmaceuticals, Inc. | 20 | $345 |
| Almatica Pharma LLC | 13 | $278 |
| Shire North American Group Inc | 12 | $203 |
| Neos Therapeutics, LP | 9 | $158 |
| Jazz Pharmaceuticals Inc. | 6 | $124 |
| Alfasigma USA, Inc. | 4 | $82 |
| Idorsia Pharmaceuticals US Inc | 4 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
| Arbor Pharmaceuticals, Inc. | 1 | $37 |
| Adlon Therapeutics L.p. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| OWP Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,631 in reported general payments places this provider in the 90th percentile of 80 child & adolescent psychiatry providers in Arizona.
See all child & adolescent psychiatry providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 14 | $27,835 |
| Ziprasidone Hcl | 24 | $1,728 |
| Olanzapine | 22 | $1,153 |
| Duloxetine Hcl | 23 | $881 |
| Quetiapine Fumarate | 22 | $682 |
| Aripiprazole | 42 | $666 |
| Bupropion XlBupropion Hcl | 26 | $654 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $529 |
| Lamotrigine | 59 | $524 |
| Clonazepam | 50 | $520 |
| Trazodone Hcl | 44 | $512 |
| Bupropion Hcl SrBupropion Hcl | 19 | $447 |
| Fluoxetine Hcl | 18 | $403 |
| Sertraline Hcl | 28 | $355 |
| Alprazolam | 49 | $329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,694 | $27,83514 claims |
| Almatica Pharma LLCSertraline Hcl | $278 | $35528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 80 child & adolescent psychiatry providers in Arizona.
Other child & adolescent psychiatry in Scottsdale
- Ramiro GuillenScottsdale$31K
- Linda KalivasScottsdale$13K
- Kenneth ZwierScottsdale$7K
- Roya KarbakhshScottsdale$6K
- Fariba PfitznerScottsdale$5K
- Shaili PatelScottsdale$3K
- Marilyn Pupo GuillenScottsdale$2K
- Lilia Romero-BoschScottsdale$1K
- Patricia Tagle-LevyScottsdale$732
- Sandeep KaurScottsdale$626
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.